Breakpoint Therapeutics GmbH
Breakpoint Therapeutics GmbH is a biotechnology company focused on modulating DNA damage responses to cure cancer.
Classification
Profile
Funding
Developing targeted cancer therapies that modulate DNA damage response pathways to kill cancer cells without harming healthy cells.
pharmaceutical companies and biotech firms via licensing or partnership deals for drug candidates
Out-Licensing Fees & Milestones - Up-front payments, development milestones, and royalty streams from pharma partners · Equity Upside - Future IPO or acquisition proceeds shared with early investors and founders · Grant & Public Funding - Potential EU Horizon or German Federal grants for innovative oncology research
channel partners
Collaborations with scientific advisors and investors to support drug development and validation.
Research and development costs associated with creating drug candidates that interfere with DNA repair mechanisms.
Proprietary technology for modulating DNA damage responses and a specialized management and advisory team.
Developing targeted cancer therapies and leveraging new insights to precisely interfere with DNA repair in cancer cells.
Strategic Partnerships - Co-development or out-licensing agreements that embed Breakpoint as a technology partner rather than a simple suppl · Investor Stewardship - Quarterly updates, board representation from investors, and transparent milestone reporting · Scientific Community Engagement - Publication of pre-clinical data, conference abstracts,
Competes in the targeted cancer therapy space by modulating DNA damage response pathways, aiming for selective toxicity against cancer cells.
Need for cancer treatments that effectively kill tumor cells while minimizing damage to healthy tissue.
- Diversify Funding Sources - Pursue EU Horizon Europe grants or German Federal Innovation Grants to extend runway beyond the seed round an
- Map Current Pipeline to Specific Pharma Needs - Conduct a 2-week interview series with R&D heads at top-10 oncology pharma to align DDR t
Value Proposition ↔ Customer Segments - DDR-focused oncology drugs directly address pharma’s unmet need for resistance-busting therapies · Key Resources ↔ Key Activities - Evotec’s platform enables rapid target validation, feeding the lead-optimization pipeline · Channels ↔ Revenue Streams - Conference exposure drives licensing talks, which generat
- Strong Investor Backing - €30 M from a reputable biotech VC consortium (Medicxi, Taiho Ventures) signals confidence in the science and bu
Team details not yet available.
No investors recorded yet.